Linnaeus Therapeutics

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma

By: Charissa On: April 6, 2022 In: Linnaeus, Portfolio News

Linnaeus Therapeutics announced it has been awarded a Phase 2 Bridge Small Business Innovation Research ("SBIR") Award by the...

Read more
Behavioral Signals

Behavioral Signals Named as a Sample Vendor in the Gartner Hype Cycle for Natural Language Technologies, 2020

By: Charissa On: August 6, 2020 In: Behavioral Signals, Portfolio News

Gartner report, Hype Cycle for Natural Language Technologies, 2020, names Behavioral Signals as a Sample Vendor in Emotion AI....

Read more
Subscribe to Kairos News
Categories